Skip to content

Serotonin: all studies

Page 401 of 401: studies 4,001 to 4,004 of 4,004, newest first. Back to the serotonin overview

Research

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)

Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman et al. preprint

Background: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also officially known as Mebufotenin, is a naturally occurring serotonergic psychedelic alkaloid found in the venom of the Sonoran Desert toad (Incilius alvarius) and various plant species. Areas of Uncertainty: Trace levels of 5-MeO-DMT may be produced endogenously in humans, but its physiological role remains unclear. Safety profiles...

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part III. N,N-dimethyltryptamine (DMT) and Ayahuasca

Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al. preprint

Background: N,N-dimethyltryptamine (DMT) is a naturally-occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase (MAO) inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT.Areas...

Membrane Permeation of Psychedelic Compounds

ChemRxiv Vito Federico Palmisano, Claudio Agnorelli, Andrea Fagiolini et al. preprint

Renewed scientific interest in psychedelic compounds represents one of the most promising avenues for addressing the current burden of mental health disorders. Classic psychedelics are a group of compounds that exhibit structural similarities to the naturally occurring neurotransmitter serotonin (5-HT). Acting on the 5-HT type 2A receptors (5-HT2AR), psychedelics induce enduring...

DOI: 10.26434/chemrxiv-2023-wlxmw (opens in new tab) Psychedelics Drug design Membrane permeation Mental health +1

Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging

bioRxiv (Cold Spring Harbor Laboratory) Hanna M. Tolle, Andrea I. Luppi, Timothy Lawn et al. 1 citation preprint

Conventional antidepressants show moderate efficacy in treating major depressive disorder. Psychedelic-assisted therapy holds promise, yet individual responses vary, underscoring the need for predictive tools to guide treatment selection. Here, we present graphTRIP (graph-based Treatment Response Interpretability and Prediction) – a geometric deep learning architecture that enables three...

DOI: 10.1101/2025.07.02.662710 (opens in new tab) Psychedelic therapy Depression treatment Antidepressant therapy Mdd treatment +19